QYQingping Yao

Qingping Yao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qingping Yao has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Brianne Navetta-Modrov

    Division of Rheumatology, Allergy and Immunology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, United States

    7 shared publications
  • Peter D. Gorevic

    6 shared publications
  • Bo Shen

    Center for Interventional Inflammatory Bowel Disease, Columbia University Irving Medical Center, New York, USA

    5 shared publications
  • Hafsa Nomani

    Division of Rheumatology, Allergy and Immunology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, United States

    5 shared publications
  • Min Shen

    Department of Rare Diseases, Peking Union Medical College Hospital, Beijing, China

    5 shared publications
  • Asha Patnaik

    Division of Rheumatology, Allergy and Immunology, Stony Brook University Renaissance School of Medicine , Stony Brook, NY, USA

    4 shared publications

Latest Publications

  • Open Access

    Challenging traditional classifications: Gene penetrance in genetically transitional disease

    by Peter D. Gorevic, Timothy B. Niewold, Ivona Aksentijevich, Gerald Pfeffer, Joan Guitart, Grant S. Schulert, Madhuri Hegde, Russell Bowler, Greg Gibson, Qingping Yao


  • NOD2-Related Multisystem Inflammatory Disorders and Recent Advances

    by Di Wu, Tomoko Matsuda, Danielle Xie, Min Shen, Atika Dhar, John M. Davis, Bo Shen, Naotomo Kambe, Warren Strober, Qingping Yao

    Nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is an intracellular innate immune sensor. Its functions have been extensively studied. Variants in the NOD2 gene are associated with several human diseases. This report provides a comprehensive review of these diseases and biomedical and immunological roles of NOD2. Blau syndrome is an autosomal dominant disease primarily occurring in children and is caused by highly penetrant NOD2 variants. Approximately 40% of Caucasian patients with Crohn's disease (CD) are associated with three main NOD2 variants of low penetrance. Yao syndrome (YAOS), a recently reported novel disease, possesses characteristic clinical pattern or constellation of recurrent fever, dermatitis, arthralgia, distal leg swelling, gastrointestinal, sicca-like symptoms, and eyelid swelling among others. This disease is associated with specific NOD2 variants including the CD-associated three main variants. Our recent large case-control study of population genetics and haplotype analyses confirms the association between certain NOD2 variants and YAOS and the coinheritance in cis of the commonly encountered variants. Molecular testing is required for the diagnosis of YAOS. The prevalence of the disease is estimated to approach that of CD. There are identified effective drugs to manage this condition. Functional studies of NOD2 have revealed its contribution to both innate and adaptive immune responses, and there are interplays between these cellular components and cytokines. NOD2 has been extensively studied for innate immune response. Specific NOD2 variants are associated with different diseases, highlighting the fact that the same genotype can contribute to different phenotypes. Further studies are warranted to focus on adaptive immunity and bridge the gap between innate and adaptive immune responses in individual diseases.


  • Utilization of the All of Us Research Program in a study of genetics in Yao syndrome

    by Song Wu, Zuoming Deng, Asif Uddin, Baozhong Xin, Peter D. Gorevic, Qingping Yao


  • Open Access

    Genetically Transitional Disease and the Road to Personalized Medicine

    by Qingping Yao, Peter D. Gorevic, Greg Gibson

    Genetically transitional disease (GTD) is emerging as a new concept in genomic medicine to straddle between the traditional binary classification of monogenic and polygenic disease. Genetic testing result reports in molecular laboratories have been predicated on the monogenic disease model, which focuses on pathogenic and likely pathogenic variants. While variants of uncertain significance (VUS) are reported by laboratories, there are challenges with regard to their clinical application so that these variants are often dismissed by ordering physicians. Unlike Mendelian disorders, where genetic variants are of high penetrance and highly probabilistic, the GTD concept is employed to highlight the impact of low-to-moderate effect gene variants whose influence on disease is modified by the genetic background. The GTD concept may explain health conditions associated with variants that are necessary but not sufficient for pathogenesis, lying in the mid gray zone between Mendelian and polygenic diseases. Although VUSs may not reach the level of pathogenicity based on American College of Medical Genetics and Genomics guidelines, they could be provisionally classified as GTD-associated variants to annotate and interpret the relationship between VUS and human genetic disease. The appropriate implementation of the GTD concept could impact patient care and research by focusing attention on the individual variability of responses in various diseases.


  • Open Access

    Editorial: Basic, clinical, and translational studies of Yao syndrome and other NOD2 related diseases

    by John M. Davis, Christine McDonald, Qingping Yao

    Nucleotide-binding oligomerization domain containing protein 2 (NOD2) is a member of NOD-like receptor family (NLRs) (1). The NLR family was first discovered in the early 2000s through the complementary efforts of several research teams, which resulted in multiple names for the same molecule (2)(3)(4)(5)(6). The family nomenclature has since been standardized; however earlier literature may refer to NOD2 as caspase recruitment domain-containing protein 15 (CARD15) based on its molecular structure that includes two N-terminal CARDs. NOD2 is an intracellular microbe sensor that plays important roles in infection defense, control of inflammation, and apoptosis (7). The discovery that NOD2 missense and frameshift mutations are risk factors for the inflammatory bowel disease Crohn's disease demonstrates the importance of this molecule in inflammatory disease (8,9). Additional genetic variants of NOD2 are linked to other autoinflammatory diseases, such as Blau syndrome and Yao syndrome (10); however, much more needs to be done to define clinical phenotypes of NOD2-associated diseases and understand the molecular mechanisms underlying disease pathogenesis. The research topic "Basic, clinical, and translational studies of Yao syndrome and other NOD2 related diseases" brings together several articles to provide further insights into this area and proposes a new concept for defining autoinflammatory diseases.In 2002, several highly penetrant variants on exon 4 of NOD2 were found to cause Blau syndrome (BS, OMIM#186580), a pediatric (early onset) autosomal dominant granulomatous disease characterized by granulomatous arthritis, uveitis, and dermatitis (11). Initially, these NOD2 variants were thought to result in overactive NOD2-dependent pro-inflammatory signaling (12); however, more recent studies indicate that the loss of NOD2 cross-regulatory function controlling the activity of other inflammatory pathways (13) may be a greater contributor to the pathobiology of BS. In this collection, two articles investigate strategies targeting these altered NOD2 activities in novel treatment approaches for BS. Multiple immune suppressive therapies have been empirically applied as BS treatments (14). The molecular biology study from Dr.Kambe's group (Ueki Y, et al). in Japan reveals that the Janus kinase inhibitor tofacitinib suppresses pro-inflammatory cytokine production through suppression of NOD2 expression. The case report from Dr. McBride's group in the US (Jensen ME, et al) demonstrates successful treatment of BS with a combination of methotrexate and hydroxychloroquine; two agents thought to interfere with expression and activation of NOD2 and other related immune sensor proteins (15,16). Although more research is needed, these findings suggest that evaluation and targeting of NOD2 expression levels may be beneficial in shaping an optimal treatment strategy for BS patients.A more recently described NOD2-associated autoinflammatory disease is Yao syndrome (YAOS, OMIM#617321) (17). YAOS is a systemic inflammatory disease characterized by recurrent fever, dermatitis, arthralgias, distal leg swelling, gastrointestinal, sicca-like symptoms and eyelid swelling to form a complete or partial clinical constellation (18) (19). This disease is linked to multiple NOD2 variants, such as IVS8+158, IVS8+158/R702W, IVS8+158/L1007fs, IVS8+158/V955I (20). Originally described as a disease that predominantly affected adult Caucasian women, five articles in this research collection expand our understanding of the presentation of YAOS in other age and ethnic groups, as well as refine the associated clinical phenotypes. The large study of 167 Greek patients with autoinflammatory disease by Dr. Laskari and colleagues (Karamanakos A, et al) reveals that 7% (12/167) or approximately half of the patients with NOD2 variants were diagnosed with YAOS and included both pediatric and adult patients. Dr. Shen and colleagues (Zhang J, et al) report on the identification of YAOS in a Chinese population and key differences in disease presentation that include a more balanced sex ratio and a higher proportion of recurrent fever and proteinuria/hematuria than found in Caucasian cohorts. Additionally, similar to genetic analyses of Crohn's disease in different ethnic groups (20), the NOD2 variants associated with Chinese YAOS patients were distinct from Caucasian populations. Further substantiating clinical and genotyping features of YAOS, Dr. Davis and colleagues reports 22 adult patients of European ancestry (Williamson KA, et al) and Dr. Yao's team provide a comprehensive study of the clinical phenotype, genotype and therapeutic response of 152 adult YAOS patients (Nomani H, et al). While there is no epidemiologic study of YAOS, the studies in this collection indicate that YAOS is more common than initially thought and impacts a broader spectrum of ethnic backgrounds. We estimate that the prevalence of this disease could approach that of Crohn's disease (25/100,000), in which up to 10-27% of patients carry NOD2 variants (21).These studies also support a new concept in genomic medicine, Genetically Transitional Disease (GTD), in which a gene mutation is necessary, but not sufficient, to cause disease alone.YAOS patients share variants associated with Crohn's disease (R702W, G908R, L1007fs), but often in combination with other NOD2 variants or variants associated with other systemic autoinflammatory diseases (SAIDs), such as MEFV, NLRP3, and NLRP12 (Nomani H, et al) (Karamanakos A, et al). GTD underscores the pervasive impact of genetic background together with environment (22). GTD straddles between monogenic and genetic complex/polygenic diseases. This concept applies to many human genetic disorders including certain rheumatic diseases (23)


  • Open Access

    Comprehensive clinical phenotype, genotype and therapy in Yao syndrome

    by Hafsa Nomani, Song Wu, Ashmia Saif, Frank Hwang, Jane Metzger, Brianne Navetta-Modrov, Peter D. Gorevic, Ivona Aksentijevich, Qingping Yao

    Objective: Yao syndrome (YAOS) is formerly called nucleotide-binding oligomerization domain containing 2 (NOD2)-associated autoinflammatory disease.We report a large cohort of YAOS.Methods: We conducted a retrospective analysis of a cohort of adult patients with systemic autoinflammatory diseases (SAIDs). All patients underwent testing for a periodic fever syndrome gene panel.Results: A total of 194 patients carried NOD2 variants, 152 patients were diagnosed with YAOS, and 42 had mixed autoinflammatory diseases with combined variants in NOD2 and other SAID-associated genes. Demographic, clinical and molecular data were summaried. In sub-group analysis of the 194 patients, individual patients were often identified to carry two or more variants that usually included IVS8 + 158/R702W, IVS8 + 158/L1007fs, IVS8 + 158/V955I, IVS8 + 158/other, or NOD2/variants in other SAID genes. Ninety-nine patients carried single variants. Taken together, these variants contribute to the disease in combination or individually.Conclusion: This largest cohort has provided comprehensive clinical and genotyping data in YAOS. Variants in the NOD2 gene can give rise to a spectrum from inflammatory bowel disease to autoinflammatory disease.This report further raises awareness of the underdiagnosed disease in the medical community.


  • Open Access

    Amyopathic dermatomyositis may be on the spectrum of autoinflammatory disease: A clinical review

    by Saika Sharmeen, Lisa Christopher-Stine, Joann N. Salvemini, Peter Gorevic, Richard Clark, Qingping Yao

    Systemic autoinflammatory diseases (SAIDs) are distinct from autoimmune diseases. The former primarily results from abnormal innate immune response and genetic testing is crucial for disease diagnosis. Similar cutaneous involvement is a main feature for both SAID and dermatomyositis (DM), so they can be confused with each other. A literature search of PubMed and MEDLINE was conducted for relevant articles. The similarities and differences between these two types of diseases were analyzed. We found phenotypic similarities between these two types of disorders. Accumulating data supports a major role of the innate immune system and a similar cytokine profile. Molecular testing using an autoinflammatory disease gene panel may help identify SAID patients from the DM population and may offer therapeutic benefit using interleukin-1 (IL-1) inhibitors. A subset of DM, notably amyopathic dermatomyositis in the absence of autoantibodies may be on the spectrum of autoinflammatory disease.


  • Genetically transitional disease: conceptual understanding and applicability to rheumatic disease

    by Timothy B. Niewold, Ivona Aksentijevich, Peter D. Gorevic, Greg Gibson, Qingping Yao

    In genomic medicine, the concept of genetically transitional disease (GTD) refers to cases in which gene mutation is necessary but not sufficient to cause disease. In this Perspective, we apply this novel concept to rheumatic diseases, which have been linked to hundreds of genetic variants via association studies. These variants are in the ‘grey zone’ between monogenic variants with large effect sizes and common susceptibility alleles with small effect sizes. Among genes associated with rare autoinflammatory diseases, many low-frequency and/or low-penetrance variants are known to increase susceptibility to systemic inflammation. In autoimmune diseases, hundreds of HLA and non-HLA genetic variants have been revealed to be modest- to moderate-risk alleles. These diseases can be reclassified as GTDs. The same concept could apply to many other human diseases. GTD could improve the reporting of genetic testing results, diagnostic yields, genetic counselling and selection of therapy, as well as facilitating research using a novel approach to human genetic diseases.


  • Management of Primary Sclerosing Cholangitis and Extraintestinal Disorders in Patients with Ileal Pouches: A Systemic Review

    by Bo Shen, QingPing M.D. Yao, Ellen Scherl

    BACKGROUND: Restorative proctocolectomy with ileal pouch-anal anastomosis improves the quality of life in patients with ulcerative colitis by the removal of diseased large bowel and preservation of the natural route of defecation. Although the surgery may improve preexisting extraintestinal manifestations in the joint, skin, and eyes, extraintestinal manifestations, particularly primary sclerosing cholangitis can persist after colectomy. OBJECTIVES: A systemic review of diagnosis and treatment of liver, joint, skin, and eye manifestations in patients with restorative proctocolectomy and ileal pouch-anal anastomosis for ulcerative colitis DATA SOURCES: PubMed, Google Scholar, and Cochrane database. STUDY SELECTION: Relevant articles on primary sclerosing cholangitis and extraintestinal manifestations in ileal pouches published between Jan 2001 and July 2023 in English were included based on Preferred Reporting Items For Systemic Review and Meta-Analysis guidelines. INTERVENTION: Diagnosis and treatment of primary sclerosing cholangitis and extraintestinal manifestations in patients with restorative proctocolectomy and ileal pouch-anal anastomosis were included. MAIN OUTCOME MEASURES: Association between primary sclerosing cholangitis, extraintestinal manifestations, and inflammatory disorders of the pouch and their management. RESULTS: The presence of primary sclerosing cholangitis and extraintestinal manifestations is associated with pouchitis, particularly chronic pouchitis. Primary sclerosing cholangitis is associated with both chronic pouchitis and enteritis, and possible pouch neoplasia. However, disease severity and disease course of primary sclerosing cholangitis and pouchitis do not appear to parallel. Despite that oral vancomycin or budesonide have been used to treat primary sclerosing cholangitis-associated pouchitis, their impact on the disease course of primary sclerosing cholangitis is not known. Biological therapy for chronic inflammatory disorders of the pouch may be also beneficial for the concurrent extraintestinal manifestations of the joints, skin, and eyes. However, studies on the correlation between the severity of inflammatory pouch disorders and the severity of joint, skin, and eye diseases are lacking. LIMITATIONS: This is a qualitative, not quantitative review of case series and case reports. CONCLUSIONS: Primary sclerosing cholangitis and extraintestinal manifestations of the joints, skin, and eyes appear to be associated with inflammatory disorders of the ileal pouch. While the treatment of pouchitis does not seem to affect the disease course of primary sclerosing cholangitis, effective therapy of inflammatory pouch disorders, particularly with biologics, likely benefits concurrent disorders of the joints, skin, and eyes. See 20-minute symposium video.